Get the Stockscreener App
48.21
2.37%
-1.17
After Hours:
48.21
Supernus Pharmaceuticals Inc stock is traded at $48.21, with a volume of 506.62K.
It is down -2.37% in the last 24 hours and down -4.14% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
See More
Previous Close:
$49.38
Open:
$49.38
24h Volume:
506.62K
Relative Volume:
0.72
Market Cap:
$2.80B
Revenue:
$718.95M
Net Income/Loss:
$-38.55M
P/E Ratio:
-70.49
EPS:
-0.6839
Net Cash Flow:
$45.99M
1W Performance:
-2.47%
1M Performance:
-4.14%
6M Performance:
+6.38%
1Y Performance:
+50.47%
1-Day Range:
$48.17
$49.83
1-Week Range:
$47.52
$50.00
52-Week Range:
$30.83
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
48.21 | 2.87B | 718.95M | -38.55M | 45.99M | -0.6839 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
SUPN PE Ratio & Valuation, Is SUPN Overvalued - Intellectia AI
Supernus CVR Milestone Triggers Cash Outflow And Undervalued Stock Debate - Yahoo Finance
Why Supernus Pharmaceuticals Shares Surged - AOL.com
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment - Investing.com
Supernus Reaches Milestone, Triggers Contingent Value Rights Payment - TipRanks
According to a contingent value rights agreement, Supernus Pharmaceuticals Inc will pay Equiniti Trust Company $0.50 per share after achieving the first milestone. - Bitget
[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event - Stock Titan
Three Growth Stocks Under Pressure: Supernus, RGA, and Black Stone MineralsNews and Statistics - IndexBox
Supernus Pharmaceuticals Q1 2026 earnings preview - MSN
Supernus Pharmaceuticals Q1 2026 Financial Results and Analyst Call HighlightsNews and Statistics - IndexBox
Trading Systems Reacting to (SUPN) Volatility - Stock Traders Daily
5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
SUPN Technical Analysis & Stock Price Forecast - Intellectia AI
Supernus Pharmaceuticals reports strong demand rebound after resolving supply constraints in March 2026 - Pluang
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Is Up 8.9% After Q1 Beat And Reaffirmed 2026 Outlook Has The Bull Case Changed? - Sahm
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded to "Strong-Buy" at Wall Street Zen - MarketBeat
Supernus (SUPN) Q1 2026 Earnings Transcript - AOL.com
Supernus Pharmaceuticals Q1 Loss Narrows To US$0.04 EPS Challenging Persistent Bearish Narrative - Sahm
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Q1 Beat And Reaffirmed Guidance - Sahm
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today - The Globe and Mail
Supernus Pharmaceuticals Reports Strong Q1 2026 Results with 56% Revenue Growth - IndexBox
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference - The Manila Times
Supernus offers May 12 webcast as CEO joins Bank of America event - Stock Titan
Does Q1 2026 Earnings Beat Reshape the Bull Case for Supernus Pharmaceuticals (SUPN)? - Yahoo Finance
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $55 - Moomoo
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2026 Earnings Call Transcript - Insider Monkey
SUPN Q1 Deep Dive: Growth Products Drive Revenue Upside, Guidance Highlights Execution Challenges - The Globe and Mail
Supernus Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Supernus outlines $840M-$870M 2026 revenue outlook as ONAPGO second-supplier filing targeted for Q3 - MSN
Supernus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Supernus Pharmaceuticals | 8-K: Supernus Announces First Quarter 2026 Financial Results - Moomoo
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Earnings call transcript: Supernus Pharmaceuticals Q1 2026 revenue beats forecast - Investing.com Canada
Supernus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
SUPERNUS PHARMACEUTICALS ($SUPN) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Supernus: Q1 Earnings Snapshot - WKYC
Q1 2026 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Four newer Supernus drugs bring in $149.1M as 2026 outlook holds - Stock Titan
[10-Q] SUPERNUS PHARMACEUTICALS, INC. Quarterly Earnings Report - Stock Titan
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates - Yahoo Finance
Supernus (NASDAQ: SUPN) posts 39% revenue growth and reaffirms 2026 outlook - Stock Titan
Supernus Announces First Quarter 2026 Financial Results - marketscreener.com
BRIEF-Supernus Pharmaceuticals Q1 Product Sales USD 150.8 Million - TradingView
Supernus faces earnings test as Onapgo launch gains traction - Investing.com
Supernus faces earnings test as Onapgo launch gains traction By Investing.com - Investing.com Canada
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):